TABLE 2.
HLA allele association with Mtb infection
| No. participants with allele | No. participants lacking allele | |||||||
|---|---|---|---|---|---|---|---|---|
| HLA allele a | HLA allele frequency (%) | Active TB & QFT+ | QFT‐ | Active TB & QFT+ | QFT‐ | Odds ratio | P‐value b | Corrected p‐value |
| DQA1*03:01 | 7.1 | 43 | 2 | 390 | 201 | 11.1 | 1.00 E‐05 | 0.001 |
| DQA1*04:01 | 13.1 | 42 | 41 | 391 | 162 | 0.4 | 3.80 E‐04 | 0.033 |
| DRB1*03:02 | 10.9 | 34 | 35 | 398 | 167 | 0.4 | 0.0006 | 0.050 |
| DQB1*04:02 | 14.8 | 50 | 44 | 382 | 159 | 0.5 | 0.001 | >0.05 |
| DQA1*01:02 | 45.9 | 217 | 75 | 216 | 128 | 1.7 | 0.002 | >0.05 |
| C*17:01 | 14.2 | 49 | 41 | 384 | 161 | 0.5 | 0.003 | >0.05 |
| A*74:01 | 5.8 | 33 | 4 | 400 | 199 | 4.1 | 0.003 | >0.05 |
| B*42:01 | 8.8 | 28 | 28 | 404 | 175 | 0.4 | 0.004 | >0.05 |
| DRB1*15:03 | 18.0 | 90 | 24 | 342 | 178 | 2.0 | 0.006 | >0.05 |
| DQB1*06:02 | 37.3 | 177 | 60 | 255 | 143 | 1.7 | 0.006 | >0.05 |
| DPA1*02:02 | 37.1 | 135 | 61 | 191 | 142 | 1.6 | 0.010 | >0.05 |
| DRB4*01:01 | 27.0 | 128 | 41 | 298 | 160 | 1.7 | 0.012 | >0.05 |
| A*30:01 | 12.1 | 43 | 34 | 390 | 169 | 0.5 | 0.018 | >0.05 |
| DQA1*01:03 | 20.6 | 78 | 53 | 355 | 150 | 0.6 | 0.021 | >0.05 |
| B*15:03 | 9.9 | 51 | 12 | 381 | 191 | 2.1 | 0.022 | >0.05 |
| DRB3*01:01 | 28.7 | 110 | 70 | 316 | 131 | 0.7 | 0.023 | >0.05 |
| DPB1*04:01 | 24.9 | 96 | 62 | 335 | 141 | 0.7 | 0.030 | >0.05 |
| DRB1*07:01 | 17.8 | 67 | 46 | 365 | 156 | 0.6 | 0.034 | >0.05 |
| DRB1*11:01 | 12.9 | 64 | 18 | 368 | 184 | 1.8 | 0.042 | >0.05 |
a
When no result was obtained for a particular locus those participants were excluded from the calculations, the total number of participants for each allele does therefore not add up to 636, or ATB (n = 99), and QFT ± (n = 537, where QFT + (n = 334), and QFT − (n = 203)).
b
Bonferroni corrected threshold for a significant p‐value = 0.0006.